



Workshop 4

Lisbon, 9 October 2015



- Facilitator: Matthias Wismar
- Experts:
 - Kate Bushby, EUCERD Joint Action and University of Newcastle (expert in Neuromuscular Genetics)
 - Victoria Hedley, EUCERD Joint Action and University of Newcastle
 - Yann Le Cam, EURORDIS
 - Teresinha Evangelista, EUCERD Joint Action and University of Newcastle
 - Stephen Lynn, EUCERD Joint Action and University of Newcastle
- Rapporteur: Christian Duffin



Programme

- Opening
- Developing thematic ERNs for rare diseases
 - Developing thematic ERNs for rare diseases: potential and challenges -Kate Bushby and Victoria Hedley
 - Group discussion 1
 - Feed-back 1

Patient focus and involvement

- Patient involvement in thematic ERNs for rare diseases: potential and challenges - Yann Le Cam
- Group discussion 2
- Feed-back 2

Conclusion



1.1 Developing thematic ERNs for rare diseases

- Think of how you would formulate and develop a <u>mission statement and</u> <u>strategic plan</u> for your network.
 - How would you describe and demonstrate the added value for networks and centres specialised in specific rare disease of working together in broader thematic networks?
 - How could the specificity of individual rare diseases be maintained within the context of thematic networks?
 - How to select a coordinating member and network coordinator for the thematic network?
 - How would you agree on the scope of services/activities that thematic networks could develop to the benefit of all members specialised in various rare diseases covered?
 - How could collaboration between different thematic networks be promoted to facilitate cross-cutting linkages between rare diseases stratified in distinct groups?
 - What are the challenges of turning existing European pilot networks into an ERN?



1.2 Patient focus and involvement

- Design a <u>patient-centredness agenda</u> of your network as part of its strategic plan
 - How should the network and its members demonstrate and document their patient-centred approach and commitment to patient empowerment?
 - How would the input and experience of patients, families and patients' association be used in the development of guidelines and pathways, quality and safety framework, outcome and performance indicators.
 - What role and responsibilities could patient organisations take in ERNs? How would you select them? How would they fit in the ERN governance model? How can they be involved in the application process?

<u>A model</u> for the purposes of grouping RD thematically

Rare immunological an	d auto-inflammatory diseases
Rare bone diseases	
Rare cancers* and tum	ours
Rare cardiac diseases	
Rare connective tissue	and musculoskeletal diseases
Rare malformations an	d developmental anomalies and rare intellectual disabilities
Rare endocrine disease	es
Rare eye diseases	
Rare gastrointestinal d	iseases
Rare gynaecological an	d obstetric diseases
Dara haamatala <i>s</i> isal	diagona

Rare haematological diseases



Rare craniofacial anomalies and ENT disorders	
Rare hepatic diseases	
Rare hereditary metabolic disorders	
Rare multi-systemic vascular diseases	
Rare neurological diseases	
Rare neuromuscular diseases	
Rare pulmonary diseases	
Rare renal diseases	
Rare skin disorders	
Rare urogenital diseases	

*Note: The networking of rare cancers is currently under discussion in EC Expert Group on Cancer Control.



www.eucerd.eu